Medgel

MedGel is a Japanese biotechnology company specializing in the development of biodegradable hydrogel-based drug delivery systems (DDS) and regenerative medicine solutions. Founded on technology developed at Kyoto University, the company's core platform utilizes a unique gelatin hydrogel that enables the sustained release of growth factors and provides a scaffold for cell proliferation. Their lead programs focus on the controlled release of basic fibroblast growth factor (bFGF) for treating critical limb ischemia and promoting bone regeneration. MedGel's technology is designed to enhance the therapeutic efficacy of proteins and cells by protecting them from degradation and ensuring localized delivery. The company collaborates with academic and clinical partners to advance its pipeline through clinical stages in Japan and internationally.